Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Safusidenib Erbumine · AB-291, DS-1001

Small molecule · developed by Nuvation Bio

Early Phase 1 Most advanced trial (none active)

NUVB Developer

1 Registered trials

What is Safusidenib Erbumine?

Safusidenib Erbumine is an oral drug given at 250 mg twice daily in 28-day cycles. It is studied in glioma, a type of brain tumor that includes astrocytoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: AB-291, DS-1001
Drug type: Small molecule
Therapy area: Oncology
Developer: Nuvation Bio Inc. (NUVB)
FDA status: Investigational, not approved in the US. Most advanced trial: Early Phase 1
UNII: 9J2M48GC2M

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05577416	Early Phase 1	Glioma	Completed	NUVB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Glioma

More from Nuvation Bio

Taletrectinib FDA approved Inixaciclib Phase 1/2 NUV-1511 Phase 1/2 NUV-868 Phase 1 Safusidenib Phase 3

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the NUVB page.

Follow NUVB, the company behind Safusidenib Erbumine

See NUVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NUVB catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z